## CLAIMS

A psychotropic agent comprising, an effective ingredient,
 at least one compound selected from the group consisting of a
 benzylisoquinoline derivative represented by general formula (I):

10

wherein  $R^1$ ,  $R^2$  and  $R^3$  each independently represent a hydrogen atom, a  $C_{1-6}$  alkyl group which may be substituted, an aryl group which may be substituted or a heteroaryl group which may be substituted, and X represents  $NR^4$  or  $N^+R^5R^6Y$  in which  $R^4$  represents a hydrogen atom or a  $C_{1-6}$  alkyl group,  $R^5$  and  $R^6$  each independently represent a hydrogen atom or a  $C_{1-6}$  alkyl group, and Y represents a halide, hydroxide, or sulfate ion; and

20

25

- a pharmaceutically acceptable salt thereof.
- 2. The psychotropic agent of Claim 1, wherein the psychotropic action is an action of preventing and/or alleviating at least one symptom selected from the group consisting of schizophrenia, depression, anxiety disorder, dysthymia, manic state, epilepsy, and sleep disorder, and/or, an action of effectuating sedation.
  - 3. A psychotropic agent for preventing and/or alleviating a

symptom selected from the group consisting of schizophrenia, depression, anxiety disorder, dysthymia, manic state, epilepsy and sleep disorder,

the agent comprising, as an effective ingredient, at least one compound selected from the group consisting of a bisbenzylisoquinoline derivative represented by general formula (II):

10

5

wherein R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup> and R<sup>11</sup> each independently represent a hydrogen atom, a C<sub>1-6</sub> alkyl group which may be substituted, an aryl group which may be substituted or a heteroaryl group which may be substituted; and

a pharmaceutically acceptable salt thereof.

20

4. The psychotropic agent of Claim 3, wherein the compound represented by general formula (II) is neferine:

5. The psychotropic agent of Claim 3, wherein the compound represented by general formula (II) is liensinine:

6. The psychotropic agent of Claim 3, wherein the compound represented by general formula (II) is isoliensinine:

25

15

7. A psychotropic health food, comprising at least one compound selected from the group consisting of a compound represented by general formula (I) described in Claim 1; and a salt thereof.

5

- 8. A health food for preventing and/or alleviating a symptom selected from the group consisting of schizophrenia, depression, anxiety disorder, dysthymia, manic state, epilepsy and sleep disorder, comprising at least one compound selected from the group consisting of a compound represented by general formula (II) described in Claim 3; and a salt thereof.
- 9. The health food of Claim 7 or 8, wherein the health food is a beverage or drinkable preparation.

15

10

10. An agent possessing an analysesic action and/or an antiinflammatory action, comprising, an effective ingredient, at least one compound selected from the group consisting of a benzylisoquinoline derivative represented by general formula (I):

20

25

wherein  $R^1$ ,  $R^2$  and  $R^3$  each independently represent a hydrogen atom, a  $C_{1-6}$  alkyl group which may be substituted, an aryl group which may

be substituted or a heteroaryl group which may be substituted, and X represents  $NR^4$  or  $N^+R^5R^6Y$  in which  $R^4$  represents a hydrogen atom or a  $C_{1-6}$  alkyl group,  $R^5$  and  $R^6$  each independently represent a hydrogen atom or a  $C_{1-6}$  alkyl group, and Y represents a halide, hydroxide, or sulfate ion;

a bisbenzylisoquinoline derivative represented by general formula (II):

10

5

wherein R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup> and R<sup>11</sup> each independently represent a hydrogen atom, a C<sub>1-6</sub> alkyl group which may be substituted, an aryl group which may be substituted or a heteroaryl group which may be substituted; and

a pharmaceutically acceptable salt thereof.

- 11. The agent of Claim 10, wherein the analgesic action and/or antiinflammatory action is an analgesic action based on an antiinflammatory action.
- 25
- 12. The agent of Claim 10 or 11, wherein the compound represented by general formula (II) is neferine:

13. A health food for preventing and/or alleviating a pain and/or an inflammation, comprising at least one compound selected from the group consisting of a compound represented by general formula (I) of Claim 10; a compound represented by general formula (II) of Claim 10; and a salt thereof.

14. The health food of Claim 13, wherein the health food is a beverage or drinkable preparation.

15. Use of at least one compound selected from the group consisting of a benzylisoquinoline derivative represented by general formula (I):

25

15

5

wherein R1, R2 and R3 each independently represent a hydrogen atom,

a C<sub>1-6</sub> alkyl group which may be substituted, an aryl group which may be substituted or a heteroaryl group which may be substituted, and X represents NR<sup>4</sup> or N<sup>+</sup>R<sup>5</sup>R<sup>6</sup>Y in which R<sup>4</sup> represents a hydrogen atom or a C<sub>1-6</sub> alkyl group, R<sup>5</sup> and R<sup>6</sup> each independently represent a hydrogen atom or a C<sub>1-6</sub> alkyl group, and Y represents a halide, hydroxide, or sulfate ion; and

a pharmaceutically acceptable salt thereof, for the manufacture of a psychotropic agent.

16. The use of Claim 15, wherein the psychotropic action is an action of preventing and/or alleviating at least one symptom selected from the group consisting of schizophrenia, depression, anxiety disorder, dysthymia, manic state, epilepsy and sleep disorder, and/or, an action of effectuating sedation.

15

10

5

17. Use of at least one compound selected from the group consisting of a bisbenzylisoquinoline derivative represented by general formula (II):

20

25

wherein  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$  and  $R^{11}$  each independently represent a hydrogen atom, a  $C_{1-6}$  alkyl group which may be substituted, an aryl

group which may be substituted or a heteroaryl group which may be substituted; and

a pharmaceutically acceptable salt thereof,

for the manufacture of a psychotropic agent for preventing and/or alleviating a symptom selected from the group consisting of schizophrenia, depression, anxiety disorder, dysthymia, manic state, epilepsy and sleep disorder.

18. The use of Claim 17, wherein the compound represented by general formula (II) is neferine:

19. The use of Claim 17, wherein the compound represented by general formula (II) is liensinine:

15

20. The use of Claim 17, wherein the compound represented by general formula (II) is isoliensinine:

10

5

21. Use of at least one compound selected from the group consisting of a benzylisoquinoline derivative represented by general formula (I) described in Claim 15, and a pharmaceutically acceptable salt thereof, for the manufacture of a psychotropic health food.

15

- 22. Use of at least one compound selected from the group consisting of a bisbenzylisoquinoline derivative represented by general formula (II) of Claim 17; and a pharmaceutically acceptable salt thereof, for the manufacture of a health food for preventing and/or alleviating a symptom selected from the group consisting of schizophrenia, depression, anxiety disorder, dysthymia, manic state, epilepsy and sleep disorder.
- 23. The use of Claim 21 or 22, wherein the health food is a beverage or drinkable preparation.
  - 24. Use of at least one compound selected from the group

consisting of a benzylisoquinoline derivative represented by general formula (I):

5

10

20

25

wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> each independently represent a hydrogen atom, a C<sub>1-6</sub> alkyl group which may be substituted, an aryl group which may be substituted or a heteroaryl group which may be substituted, and X represents NR<sup>4</sup> or N<sup>+</sup>R<sup>5</sup>R<sup>6</sup>Y in which R<sup>4</sup> represents a hydrogen atom or a C<sub>1-6</sub> alkyl group, R<sup>5</sup> and R<sup>6</sup> each independently represent a hydrogen atom or a C<sub>1-6</sub> alkyl group, and Y represents a halide, hydroxide, or sulfate ion;

a bisbenzylisoquinoline derivative represented by general formula (II):

wherein R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup> and R<sup>11</sup> each independently represent a hydrogen atom, a C<sub>1-6</sub> alkyl group which may be substituted, an aryl group which may be substituted or a heteroaryl group which may be substituted; and

a pharmaceutically acceptable salt thereof,

15

25

for the manufacture of an agent possessing an analgesic action and/or an antiinflammatory action.

- 5 25. The use of Claim 24, wherein the analgesic action and/or antiinflammatory action is an analgesic action based on an ntiinflammatory action.
- 26. The use of Claim 24 or 25, wherein the compound represented by general formula (II) is neferine:

27. Use of at least one compound selected from the group consisting of a compound represented by general formula (I) of Claim 24; a compound represented by general formula (II) of Claim 24; and a salt thereof, for the manufacture of a health food for preventing and/or alleviating a pain and/or an inflammation.

28. The use of Claim 27, wherein the health food is a beverage or drinkable preparation.

29. A method for preventing and/or alleviating a psychiatric disorder, and/or for effectuating sedation, comprising administering to a patient in need thereof, as an effective ingredient, at least one compound selected from the group consisting of a benzylisoquinoline derivative represented by general formula (I):

$$R^{1}O$$
 $X$ 
 $OR^{3}$ 

10

15

5

wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> each independently represent a hydrogen atom, a C<sub>1-6</sub> alkyl group which may be substituted, an aryl group which may be substituted or a heteroaryl group which may be substituted; and X represents NR<sup>4</sup> or N<sup>+</sup>R<sup>5</sup>R<sup>6</sup>Y in which R<sup>4</sup> represents a hydrogen atom or a C<sub>1-6</sub> alkyl group; R<sup>5</sup> and R<sup>6</sup> each independently represent a hydrogen atom or a C<sub>1-6</sub> alkyl group; and Y represents a halide, hydroxide, or sulfate ion; and

a pharmaceutically acceptable salt thereof.

20

30. The method of Claim 29, wherein the psychiatric disorder is at least one symptom selected from the group consisting of schizophrenia, depression, anxiety disorder, dysthymia, manic state, epilepsy and sleep disorder.

25

31. The method of Claim 29, wherein the patient is in need of sedation.

- 32. The method of Claim 29, wherein said derivative is administered orally as part of a health food containing said derivative.
- 33. The method of Claim 32, wherein the health food is abeverage or drinkable preparation.
  - 34. A method for preventing and/or alleviating a symptom selected from the group consisting of schizophrenia, depression, anxiety disorder, dysthymia, manic state, epilepsy and sleep disorder, comprising administering to a patient in need thereof, as an effective ingredient, at least one compound selected from the group consisting of a bisbenzylisoquinoline derivative represented by general formula (II):

20

10

15

wherein R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup> and R<sup>11</sup> each independently represent a hydrogen atom, a C<sub>1-6</sub> alkyl group which may be substituted, an aryl group which may be substituted or a heteroaryl group which may be substituted; and

- 25 a pharmaceutically acceptable salt thereof.
  - 35. The method of Claim 34, wherein the compound

represented by general formula (II) is neferine:

36. The method of Claim 34, wherein the compound represented by general formula (II) is liensinine:

37. The method of Claim 34, wherein the compound compound represented by general formula (II) is isoliensinine:

15

5

- 38. The method of Claim 34, wherein said derivative is administered orally as part of a health food containing said derivative.
- 39. The method of Claim 38, wherein the health food is abeverage or drinkable preparation.
  - 40. A method for bringing about a psychotropic action, comprising administering to a patient in need thereof, as an effective ingredient, at least one compound selected from the group consisting of a benzylisoquinoline derivative represented by general formula (I):

$$R^{1}O$$
 $R^{2}O$ 
 $OR^{3}$ 

15

10

wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> each independently represents a hydrogen atom, a C<sub>1-6</sub> alkyl group which may be substituted, an aryl group which may be substituted or a heteroaryl group which may be substituted; and X represents NR<sup>4</sup> or N<sup>+</sup>R<sup>5</sup>R<sup>6</sup>Y in which R<sup>4</sup> represents a hydrogen atom or a C<sub>1-6</sub> alkyl group; R<sup>5</sup> and R<sup>6</sup> each independently represent a hydrogen atom or a C<sub>1-6</sub> alkyl group; and Y represents a halide, hydroxide, or sulfate ion, and

a pharmaceutically acceptable salt thereof.

25

20

41. The method of Claim 40, wherein said psychotropic action is a sedative action and said patient in need is one in need of sedation.

- 42. The method of Claim 40, wherein said psychotropic action is the alleviation of a psychiatric disorder and said patient in need is one having at least one symptom selected from the group consisting of schizophrenia, depression, anxiety disorder, dysthymia, manic state, epilepsy and sleep disorder.
- 43. A method for preventing and/or treating a pain and/or an inflammation, comprising administering to a patient in need thereof, as an effective ingredient, at least one compound selected from the group consisting of a benzylisoquinoline derivative represented by general formula (I):

$$R^{1}O$$
 $R^{2}O$ 
 $OR^{3}$ 

5

10

20

wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> each independently represent a hydrogen atom, a C<sub>1-6</sub> alkyl group which may be substituted, an aryl group which may be substituted or a heteroaryl group which may be substituted, and X represents NR<sup>4</sup> or N<sup>+</sup>R<sup>5</sup>R<sup>6</sup>Y in which R<sup>4</sup> represents a hydrogen atom or a C<sub>1-6</sub> alkyl group, R<sup>5</sup> and R<sup>6</sup> each independently represent a hydrogen atom or a C<sub>1-6</sub> alkyl group, and Y represents a halide, hydroxide, or sulfate ion;

25 a bisbenzylisoquinoline derivative represented by general formula (II):

wherein R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup> and R<sup>11</sup> each independently represent a hydrogen atom, a C<sub>1-6</sub> alkyl group which may be substituted, an aryl group which may be substituted or a heteroaryl group which may be substituted; and

a pharmaceutically acceptable salt thereof.

- 15 44. The method of Claim 43, wherein a pain based on inflammation is prevented and/or treated.
  - 45. The method of Claim 43 or 44, wherein the compound represented by general formula (II) is neferine:

5

- 46. The method of Claim 43, wherein said derivative is administered orally as part of a health food containing said derivative.
- 47. The method of Claim 46, wherein the health food is a beverage or drinkable preparation.